Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2008

01-04-2008 | Case Report

A case of malignant eccrine spiradenoma metastatic to intramammary lymph node

Authors: Yuko Tanaka, Ekapot Bhunchet, Toshikatsu Shibata

Published in: Breast Cancer | Issue 2/2008

Login to get access

Abstract

Eccrine spiradenoma (ES) is a fairly common, benign, cutaneous tumor originating from the sweat glands. In contrast, the malignant counterpart of ES, malignant eccrine spiradenoma (MES), is extremely rare. A long-standing lesion rarely begins to enlarge rapidly. A growth that results in ulceration or discoloration may be associated with malignant transformation. We present the first reported case of this tumor metastasizing to an intramammary lymph node (IMLN). The uncommon metastasizing focus of the periumbilical MES and its histopathological similarity with a primary breast carcinoma made the diagnosis difficult.
Literature
1.
Saboorian MH, Kenny M, Ashfaq R, Albores-Saavedra J. Carcinosarcoma arising in eccrine spiradenoma of the breast. Arch Pathol Lab Med. 1996;120:501–4.PubMed
2.
Thomas B, Duwel V, Proot L, Vanvuchelen J. An uncommon breast tumor: the malignant eccrine spiradenoma. Acta Chir Belg. 1993;93:295–8.PubMed
3.
Hantash BM, Chan JL, Egbert BM, Gladstone HB. De novo malignant eccrine spiradenoma; a case report and review of the literature. Dermatol Surg. 2006;32:1189–98.PubMedCrossRef
4.
Tasaki I, Mukae N, Hirata R, Kondo S, Sanefuji H. Malignant eccrine spiradenoma: a case report. JPN J Plast Reconstr Surg. 2002;45:473–8. (In Japanese).
5.
Izumi K, Niizeki H, Ikutomi M. A case of malignant eccrine spiradenoma. J JOCD. 1992;46:123–8. (In Japanese).
6.
Wakeyama E, Shukuwa T, Katayama I, Toriyama F. A case of malignant eccrine spiradenoma. Nishinihon J Dermatol 1999;61:62–6. (In Japanese).CrossRef
7.
McCluggage WG, Fon LJ, O’Rourke D, Ismail M, Hill CM, Parks TG, Allen DC. Malignant eccrine spiradenoma with carcinomatous and sarcomatous elements. J Clin Pathol. 1997;50:871–3.PubMedCrossRef
8.
Lever WF, Lever GS. Histopathology of the skin. In: Lever WF, Lever GS, Pedersen DD, Courant MH (eds) Eccrine spiradenoma, Malignant eccrine spiradenoma, 6th edn. Philadelphia: JB Lippincott Co; 1983. pp. 555–7.
9.
Meriggi F, Tagliabò R, Morone G, Tenti P, Zadra MF, Ricevuti G, Forni E. The potential malignancy of eccrine spiradenoma. Ital J Surg Sci. 1989;19:265–8.PubMed
10.
Mirza I, Kloss R, Sieber SC. Malignant eccrine spiradenoma. Arch Pathol Lab Med. 2002;126:591–4.PubMed
11.
Lara JF, Nadeen MA, Asaadi M. Malignant mixed tumor ex eccrine spiradenoma: an unusual pattern of malignant dedifferentiation. Ann Diagn Pathol. 2001;5:155–61.PubMedCrossRef
12.
Granter SR, Seeger K, Calonje E, Busam K, McKee PH. Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases. Am J Dermatopathol. 2000;22:97–103.PubMedCrossRef
13.
Yildirim S, Aköz T, Akan M, Ege GA. De novo malignant eccrine spiradenoma with an interesting and unusual location. Dermatol Surg. 2001;27:417–20.PubMedCrossRef
14.
Numata M, Hashimoto T, Urayama H, Nishimaki K, Noguchi T, Gibo Y. Malignant eccrine spiradenoma: report of a case and review of literature. Teishin Igaku. 1991;43:31–3.
15.
Chase DM, Basu T, Saffari B, Berman ML. Malignant eccrine spiradenoma of the vulva; a case report and review of the literature. Int Gynecol Cancer. 2006;16:1465–9.CrossRef
16.
Braun-Falco M, Bonel H, Ring J, Heint R. Linear spiradenoma with focal transformation. JEADV. 2003;17:308–12.PubMed
17.
Thompson JF, Uren RF, Shaw HM, McCarthy WH, Quinn MJ, O’Brien CJ, Howman-Giles RB. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195–204.PubMedCrossRef
18.
Uren RF, Giles RH, Chung D, Thompson JF. Nuclear medicine aspects of melanoma and breast lymphatic mapping. Semin Oncol. 2004;31:338–48.PubMedCrossRef
19.
Kouskos E, Querici GDR, Ball S, Koh DM. Metastatic intramammary lymph nodes as the primary presenting sign of breast cancer. Breast 2004;13:416–20.PubMedCrossRef
20.
Günhan-Bilgen I, Memiş A, Üstün E. Metastatic intramammary lymph nodes: mammographic and ultrasonographic features. Euro J Radiol. 2001;40:24–9.CrossRef
21.
Shen J, Hunt KK, Mirza NQ, Krishnamurthy S, Singletary SE, Kuerer HM. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer. 2004;101:1330–7.PubMedCrossRef
Metadata
Title
A case of malignant eccrine spiradenoma metastatic to intramammary lymph node
Authors
Yuko Tanaka
Ekapot Bhunchet
Toshikatsu Shibata
Publication date
01-04-2008
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-007-0023-y

Other articles of this Issue 2/2008

Breast Cancer 2/2008 Go to the issue

Conference Paper

Breast cancer: individualized diagnosis for tailored treatment

Original Article

Bilateral breast MR imaging: is it superior to conventional methods for the detection of contralateral breast cancer?

Review Article

Screening and diagnosis of breast cancer in augmented women

Conference Paper

In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine

Conference Paper

Individualization of breast cancer based on histopathological features and molecular alterations

Conference Paper

Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits